Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangxin Hong

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraCatherine S Diefenbach, Hailun Li, Fangxin Hong, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical TrialsSarah C Rutherford, Jun Yin, Levi Pederson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphomaDavid W Scott, Fong Chun Chan, Fangxin Hong, et al.
JCO Precision Oncology|April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1BAmy S Clark, Fangxin Hong, Richard S Finn, et al.
American Journal of Hematology|October 23, 2015
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaMatthew J Maurer, Jean-Philippe Jais, Hervé Ghesquières, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraCatherine S Diefenbach, Hailun Li, Fangxin Hong, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical TrialsSarah C Rutherford, Jun Yin, Levi Pederson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Cancer|September 14, 2017
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysisTara O Henderson, Susan K Parsons, Kristen E Wroblewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphomaDavid W Scott, Fong Chun Chan, Fangxin Hong, et al.
JCO Precision Oncology|April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1BAmy S Clark, Fangxin Hong, Richard S Finn, et al.
American Journal of Hematology|October 23, 2015
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaMatthew J Maurer, Jean-Philippe Jais, Hervé Ghesquières, et al.
Pageof 11